Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

National Immunization Strategy 2017-2022


Foreword
 
There have been many transformations to the NIP inthe recent years. New vaccines wereadded to the vaccination schedule, the cohorts served by the public sector kepton expandingsince the onset of the Syrian crisis, measures to consolidatethe vaccine purchasing arrangements were adopted,and there wasa leveraging up ofthe vaccinovigilanceand its effective management.In 2016, the Ministryof health in Lebanon decided that it was the time to take stock, constructon the current NIP strengthsand achievements andidentify areas for further improvement. A strategy for the NIP for 2016-2020 wasenvisagedin agreementwith the development partners. A detailed situation analysis assessment was initiatedin October 2015 in two stages: at the initial stage, the country and health system contexts were analyzed, and immunization system performance was measured. In the second stage, a framework was developed in consultations with key stakeholders to define gaps in the evidence. Immunization coverage evaluation survey was conducted in 2016 and fed into filling the lacunas in information.

The present document expresses the country vision, goals and priorities of the national immunization program. It relies on a careful examination of the situation analysis, an assessment of the enablers and challenges facing the immunization services and defines the national immunization strategies addressing these contests. The strategies were formulated as informed choices across more than one solution deemed most feasible and efficient considering the country context.

The document is structured in three sections:

Section 1“Situational analysis” presents briefly the organization and operation of the national immunization program as well as the recent achievements and remaining challenges,

Section 2 “Conceptual framework” describes the future vision of the country in regards to vaccine preventable diseases, the long term goals to be achieved and the more specific results –immunization system objectives and targets for 2020,

Section 3 defines the Strategies to address the bottlenecks and achieve immunization system objectives by 2020. Most of strategies (so called “immunization system specific” ones) are presented by relevant health system blocks.The focus of the NIP Strategy, is to assistthe MOPH to meet international goals set by the World Health Organization (WHO) under the Global Immunization Vision and Strategy (GIVS). The Strategy articulates action areas to conserve the successful achievements of the last years, built on the current favoring momentum and propose solutions for the drawbacks

The Strategy comprises nineStrategic Priority Areas to complement and strengthen the NIP.

The matrix (Figure 2) in Annexesshows expected results of the immunization system development strategies by health system building blocks and links them to the root causes (weaknesses and treats) identified during the system analysis...
    ...
    103
    ...
ATC Name B/G Ingredients Dosage Form Price
C09CA06 ANDESART 16 G Candesartan cilexetil - 16mg 16mg Tablet 665,202 L.L
C10AA07 CONSIVAS 20 G Rosuvastatin (calcium) - 20mg 20mg Tablet, film coated 450,187 L.L
D10AF01 MEDACIN T G Clindamycin (phosphate) - 10mg/ml 10mg/ml Solution 314,459 L.L
J01DC02 ZILISTEN G Cefuroxime (sodium) - 750mg 750mg Injectable dry powder 155,886 L.L
J01MA12 FLOBIOX G Levofloxacin - 750mg 750mg Tablet, film coated 945,809 L.L
L04AA31 TERAGIO G Teriflunomide - 14mg 14mg Tablet 49,451,224 L.L
M01AH01 JOSWE FLAMEX 200 G Celecoxib - 200mg 200mg Capsule 636,981 L.L
N02BE01 FEBRADOL JOINT G Paracetamol - 665mg 665mg Tablet 289,246 L.L
N06AX16 DEFAXINE G Venlafaxine (HCl) - 75mg 75mg Capsule, extended release 724,395 L.L
R03AK07 BUFOMIX EASYHALER G Formoterol fumarate dihydrate - 4.5mcg/inhalation, Budesonide - 160mcg/inhalation Metered dose inhaler 1,182,581 L.L
S01AA12 TOBRIN G Tobramycin - 0.3% 0.3% Drops 169,324 L.L
A02BC04 RABEC G Rabeprazole (sodium) - 10mg 10mg Tablet, film coated 212,327 L.L
A08AB01 LESSFAT G Orlistat - 60mg 60mg Capsule 1,039,238 L.L
A11CC05 D-VITAL G Vitamin D3 - 10,000IU 10,000IU Capsule 561,342 L.L
B03AA02 FERRATE G Ferrous fumarate - 20mg/ml (iron element) 20mg/ml Suspension 667,890 L.L
B05D PERITONEAL DIALYSIS SOLUTION WITH 1 1/2% DEXTROSE G Sodium lactate - 0.392g%, Calcium chloride, 2H2O - 0.0257g%, Magnesium chloride, 6H2O - 0.0153g%, Sodium chloride - 0.567g%, Dextrose, H2O - 1.5g% Injectable solution 490,807 L.L
C09CA06 ARKANDA 16 G Candesartan cilexetil - 16mg 16mg Tablet 700,078 L.L
C10AA07 CRESOTAB G Rosuvastatin (calcium) - 20mg 20mg Tablet, film coated 517,379 L.L
D10AF01 CLINIDERM G Clindamycin (phosphate) - 1% 1% Gel 712,876 L.L
G04BX14 DEPOJOY G Dapoxetine (hydrochloride) - 30mg 30mg Tablet, film coated 1,565,577 L.L
J01MA12 JOSWE AVOXIN 750 G Levofloxacin - 750mg 750mg Tablet, film coated 1,550,794 L.L
L04AA31 TERAGIO G Teriflunomide - 14mg 14mg Tablet 23,076,914 L.L
M01AH01 NORMOCOXIB G Celecoxib - 200mg 200mg Capsule, hard 798,242 L.L
N04BC07 DACEPTON G Apomorphine HCl - 30mg/3ml 30mg/3ml Injectable solution 13,404,432 L.L
N06AX16 DEPREVIX HELLAS G Venlafaxine - 75mg 75mg Capsule, prolonged release 564,414 L.L
S01AA12 TOBRACIN G Tobramycin - 0.3% 0.3% Ointment 280,863 L.L
A02BC04 RAMEP G Rabeprazole (sodium) - 10mg 10mg Tablet, gastroresistant 795,310 L.L
A11CC05 EURO D 10000 IU G Vitamin D3 - 10,000IU 10,000IU Capsule 993,100 L.L
B03AA02 FEOSTA G Ferrous fumarate - 200mg 200mg Tablet, film coated 682,160 L.L
B05D CAPD/DPCA 17Solution for peritoneal dialysis stay safe G Sodium chloride - 5.786g/l, Sodium-(S)-lactate - 3.925g/l, Calcium chloride 2H2O - 0.1838g/l, Magnesium chloride, 6H2O - 0.1017g/l, Anhydrous glucose - 15g/l, Fructose , - up to 0.75g/l Injectable solution 605,921 L.L
    ...
    103
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2025